title: Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
abstract: Isavuconazole is a new extended-spectrum triazole with activity against yeasts, molds, and dimorphic fungi. It is approved for the treatment of invasive aspergillosis and mucormycosis. Advantages of this triazole include the availability of a water-soluble intravenous formulation, excellent bioavailability of the oral formulation, and predictable pharmacokinetics in adults. A randomized, double-blind comparison clinical trial for treatment of invasive aspergillosis found that the efficacy of isavuconazole was noninferior to that of voriconazole. An open-label trial that studied primary as well as salvage therapy of invasive mucormycosis showed efficacy with isavuconazole that was similar to that reported for amphotericin B and posaconazole. In patients in these studies, as well as in normal volunteers, isavuconazole was well tolerated, appeared to have few serious adverse effects, and had fewer drug-drug interactions than those noted with voriconazole. As clinical experience increases, the role of this new triazole in the treatment of invasive fungal infections will be better defined.
authors.affiliation: Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Health System.
authors.forename: Marisa H
authors.initials: MH
authors.lastname: Miceli
authors.affiliation: Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Health System Veterans Affairs Ann Arbor Healthcare System, Michigan.
authors.forename: Carol A
authors.initials: CA
authors.lastname: Kauffman
mesh_terms: D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D055744:Invasive Pulmonary Aspergillosis / Q000188:drug therapy*; D009091:Mucormycosis / Q000188:drug therapy*; D009570:Nitriles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D009570:Nitriles; D011725:Pyridines; D014230:Triazoles; C508735:isavuconazole
keywords: aspergillosis; isavuconazole; isavuconazonium sulfate; mucormycosis; triazoles